JPWO2020249802A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020249802A5 JPWO2020249802A5 JP2021574160A JP2021574160A JPWO2020249802A5 JP WO2020249802 A5 JPWO2020249802 A5 JP WO2020249802A5 JP 2021574160 A JP2021574160 A JP 2021574160A JP 2021574160 A JP2021574160 A JP 2021574160A JP WO2020249802 A5 JPWO2020249802 A5 JP WO2020249802A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazolo
- phenyl
- pyrazin
- pharmaceutically acceptable
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 description 41
- 150000001875 compounds Chemical class 0.000 description 36
- 150000001204 N-oxides Chemical class 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 239000012453 solvate Substances 0.000 description 32
- 230000000155 isotopic effect Effects 0.000 description 30
- 125000000217 alkyl group Chemical group 0.000 description 25
- 125000001475 halogen functional group Chemical group 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 108010054200 NR2B NMDA receptor Proteins 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 208000020925 Bipolar disease Diseases 0.000 description 5
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 5
- 208000024714 major depressive disease Diseases 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- GBLNDNAYYKAUFP-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)F GBLNDNAYYKAUFP-UHFFFAOYSA-N 0.000 description 2
- RBLOXPJEKUFWRR-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CC(C1)F)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CC(C1)F)F RBLOXPJEKUFWRR-UHFFFAOYSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- TTZRLXBWNZJHHQ-UHFFFAOYSA-N N1(CCC1)C(CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)F)C(F)F)=O Chemical compound N1(CCC1)C(CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)F)C(F)F)=O TTZRLXBWNZJHHQ-UHFFFAOYSA-N 0.000 description 2
- IXRLNMUIQZVMFX-UHFFFAOYSA-N N1(CCC1)C(CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)F)OC(F)F)=O Chemical compound N1(CCC1)C(CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)F)OC(F)F)=O IXRLNMUIQZVMFX-UHFFFAOYSA-N 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 201000009916 Postpartum depression Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 208000012672 seasonal affective disease Diseases 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- AAOZRHVRDQSARF-UHFFFAOYSA-N CN(C(CN1N=CC=2C1=NC(=CN=2)C1=C(C(=C(C=C1)F)F)F)=O)C Chemical compound CN(C(CN1N=CC=2C1=NC(=CN=2)C1=C(C(=C(C=C1)F)F)F)=O)C AAOZRHVRDQSARF-UHFFFAOYSA-N 0.000 description 1
- JNYQDPROFWFJPS-UHFFFAOYSA-N CN(C(CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C(=C1)F)F)F)=O)C Chemical compound CN(C(CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C(=C1)F)F)F)=O)C JNYQDPROFWFJPS-UHFFFAOYSA-N 0.000 description 1
- LKWUFUPHODNGCL-UHFFFAOYSA-N CN(C(CN1N=CC=2C1=NC(=CN=2)C1=CC=C(C=C1)OC(F)(F)F)=O)C Chemical compound CN(C(CN1N=CC=2C1=NC(=CN=2)C1=CC=C(C=C1)OC(F)(F)F)=O)C LKWUFUPHODNGCL-UHFFFAOYSA-N 0.000 description 1
- LCDPBVRJMYILSR-UHFFFAOYSA-N CN(C(CN1N=CC=2C1=NC(=CN=2)C=1C=C(C=CC=1)C)=O)C Chemical compound CN(C(CN1N=CC=2C1=NC(=CN=2)C=1C=C(C=CC=1)C)=O)C LCDPBVRJMYILSR-UHFFFAOYSA-N 0.000 description 1
- IMHDZWHPHBMGIE-UHFFFAOYSA-N CN(C(CN1N=CC=2C1=NC(=CN=2)C=1SC(=CC=1)C(F)(F)F)=O)C Chemical compound CN(C(CN1N=CC=2C1=NC(=CN=2)C=1SC(=CC=1)C(F)(F)F)=O)C IMHDZWHPHBMGIE-UHFFFAOYSA-N 0.000 description 1
- HEBCYPCRSNKTAF-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)C1CC1)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)C1CC1)OC(F)F HEBCYPCRSNKTAF-UHFFFAOYSA-N 0.000 description 1
- FKZVAXOHLDEFKE-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)C Chemical compound ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)C FKZVAXOHLDEFKE-UHFFFAOYSA-N 0.000 description 1
- PGUSMLAGGBLAGG-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)C(C)(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)C(C)(F)F PGUSMLAGGBLAGG-UHFFFAOYSA-N 0.000 description 1
- GJNBHJPXHVYXGR-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)C(F)(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)C(F)(F)F GJNBHJPXHVYXGR-UHFFFAOYSA-N 0.000 description 1
- JTEVWDRCYNJPPN-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)C(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)C(F)F JTEVWDRCYNJPPN-UHFFFAOYSA-N 0.000 description 1
- ZEGOLYSWZUNBPO-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)F ZEGOLYSWZUNBPO-UHFFFAOYSA-N 0.000 description 1
- DUVBQXRHTBPQOW-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)OC(F)F DUVBQXRHTBPQOW-UHFFFAOYSA-N 0.000 description 1
- YWNNRGULGCNVQO-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CC(C1)C)C(C)(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CC(C1)C)C(C)(F)F YWNNRGULGCNVQO-UHFFFAOYSA-N 0.000 description 1
- RFVCNHMCJRKMSD-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CC(C1)F)C(C)(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CC(C1)F)C(C)(F)F RFVCNHMCJRKMSD-UHFFFAOYSA-N 0.000 description 1
- IURUTYKQKVNQNC-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CCOCC1)C(C)(F)F Chemical compound ClC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CCOCC1)C(C)(F)F IURUTYKQKVNQNC-UHFFFAOYSA-N 0.000 description 1
- TVIVCHILSPWNAD-UHFFFAOYSA-N ClC1=CC(=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)F Chemical compound ClC1=CC(=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)F TVIVCHILSPWNAD-UHFFFAOYSA-N 0.000 description 1
- FVNOAZVTIHSMHE-UHFFFAOYSA-N ClC=1C=C(C=CC=1OC(F)(F)F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C Chemical compound ClC=1C=C(C=CC=1OC(F)(F)F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C FVNOAZVTIHSMHE-UHFFFAOYSA-N 0.000 description 1
- GVVYIZOSZOISFT-UHFFFAOYSA-N ClC=1C=C(C=CC=1OC)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C Chemical compound ClC=1C=C(C=CC=1OC)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C GVVYIZOSZOISFT-UHFFFAOYSA-N 0.000 description 1
- FRZCKJSLGGMESU-UHFFFAOYSA-N ClC=1C=C(C=NC=1)CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)F)C(F)F Chemical compound ClC=1C=C(C=NC=1)CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)F)C(F)F FRZCKJSLGGMESU-UHFFFAOYSA-N 0.000 description 1
- ORIAFLHNPYUBCF-UHFFFAOYSA-N ClC=1C=C(C=NC=1)CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)F)OC(F)F Chemical compound ClC=1C=C(C=NC=1)CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)F)OC(F)F ORIAFLHNPYUBCF-UHFFFAOYSA-N 0.000 description 1
- ZCTFPORQQFLBHD-UHFFFAOYSA-N FC(C)(F)C1=CC=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C Chemical compound FC(C)(F)C1=CC=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C ZCTFPORQQFLBHD-UHFFFAOYSA-N 0.000 description 1
- LHBZNIDYEMZRRU-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C Chemical compound FC(C)(F)C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C LHBZNIDYEMZRRU-UHFFFAOYSA-N 0.000 description 1
- XJYIEVAUZRWRHY-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CC(C1)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CC(C1)C)F XJYIEVAUZRWRHY-UHFFFAOYSA-N 0.000 description 1
- LIQVIOUAKIQRQT-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(CC)=O)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(CC)=O)F LIQVIOUAKIQRQT-UHFFFAOYSA-N 0.000 description 1
- DTAUTFUMTFMWOD-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC1=CC(=NO1)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC1=CC(=NO1)C)F DTAUTFUMTFMWOD-UHFFFAOYSA-N 0.000 description 1
- BGMFFEPGJKLEQX-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC=1C=C(C=NC=1)C#N)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC=1C=C(C=NC=1)C#N)F BGMFFEPGJKLEQX-UHFFFAOYSA-N 0.000 description 1
- NWRWNPOLEUDFHG-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC=1C=NC=C(C=1)F)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC=1C=NC=C(C=1)F)F NWRWNPOLEUDFHG-UHFFFAOYSA-N 0.000 description 1
- JZMQGFLBKWVQRW-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC=1C=NC=C(C=1)OC)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC=1C=NC=C(C=1)OC)F JZMQGFLBKWVQRW-UHFFFAOYSA-N 0.000 description 1
- MLJPZFSEJQWAKY-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC=1OC(=NN=1)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC=1OC(=NN=1)C)F MLJPZFSEJQWAKY-UHFFFAOYSA-N 0.000 description 1
- QZDGQCSVDWKSLN-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC=1SC(=NN=1)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC=1SC(=NN=1)C)F QZDGQCSVDWKSLN-UHFFFAOYSA-N 0.000 description 1
- MGIGGDRCIAESRN-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2F)CC(=O)N(C)C)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2F)CC(=O)N(C)C)F MGIGGDRCIAESRN-UHFFFAOYSA-N 0.000 description 1
- JXROHSLFYKORGZ-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2F)CC=1C=C(C=NC=1)C#N)F Chemical compound FC(C=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2F)CC=1C=C(C=NC=1)C#N)F JXROHSLFYKORGZ-UHFFFAOYSA-N 0.000 description 1
- SDKFZHOOCLPCFJ-UHFFFAOYSA-N FC(OC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)F)F Chemical compound FC(OC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)F)F SDKFZHOOCLPCFJ-UHFFFAOYSA-N 0.000 description 1
- PVXPTJNRPXQGDF-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)F PVXPTJNRPXQGDF-UHFFFAOYSA-N 0.000 description 1
- JNIWXYASRJBMMB-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CC(C1)C)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CC(C1)C)F JNIWXYASRJBMMB-UHFFFAOYSA-N 0.000 description 1
- DCGDQXJNUQIXNG-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CC(C1)F)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N1CC(C1)F)F DCGDQXJNUQIXNG-UHFFFAOYSA-N 0.000 description 1
- MOMJPBUZNOPZHP-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC1CNC(O1)=O)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC1CNC(O1)=O)F MOMJPBUZNOPZHP-UHFFFAOYSA-N 0.000 description 1
- QXNDSWJCOSCVEB-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC=1C=NC=C(C=1)OC)F Chemical compound FC(OC=1C=C(C=CC=1F)C1=CN=C2C(=N1)N(N=C2)CC=1C=NC=C(C=1)OC)F QXNDSWJCOSCVEB-UHFFFAOYSA-N 0.000 description 1
- ZUSJPPAFYRDZOM-UHFFFAOYSA-N FC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)C Chemical compound FC1=C(C=C(C=C1)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C)C ZUSJPPAFYRDZOM-UHFFFAOYSA-N 0.000 description 1
- BOJDVTXWELVPDC-UHFFFAOYSA-N FC1=C(C=C(C=C1)F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C Chemical compound FC1=C(C=C(C=C1)F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C BOJDVTXWELVPDC-UHFFFAOYSA-N 0.000 description 1
- MDOVXUYEUXFFRQ-UHFFFAOYSA-N FC1=C(C=CC(=C1C)F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C Chemical compound FC1=C(C=CC(=C1C)F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C MDOVXUYEUXFFRQ-UHFFFAOYSA-N 0.000 description 1
- SWLCJJIINVYLMV-UHFFFAOYSA-N FC=1C=C(C=C(C=1C)F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C Chemical compound FC=1C=C(C=C(C=1C)F)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C SWLCJJIINVYLMV-UHFFFAOYSA-N 0.000 description 1
- MGUHTABIHBROQN-UHFFFAOYSA-N FC=1C=C(C=CC=1C)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C Chemical compound FC=1C=C(C=CC=1C)C1=CN=C2C(=N1)N(N=C2)CC(=O)N(C)C MGUHTABIHBROQN-UHFFFAOYSA-N 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- UFZKKFLNZBYWGR-UHFFFAOYSA-N N1(CCC1)C(CN1N=C(C=2C1=NC(=CN=2)C1=CC(=C(C=C1)F)C(F)F)F)=O Chemical compound N1(CCC1)C(CN1N=C(C=2C1=NC(=CN=2)C1=CC(=C(C=C1)F)C(F)F)F)=O UFZKKFLNZBYWGR-UHFFFAOYSA-N 0.000 description 1
- QDLNSDRZLAEEOB-UHFFFAOYSA-N N1(CCC1)C(CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)Cl)C(C)(F)F)=O Chemical compound N1(CCC1)C(CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)Cl)C(C)(F)F)=O QDLNSDRZLAEEOB-UHFFFAOYSA-N 0.000 description 1
- ZFPJGIWSMISERJ-UHFFFAOYSA-N N1(CCC1)C(CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)Cl)OC(F)F)=O Chemical compound N1(CCC1)C(CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)Cl)OC(F)F)=O ZFPJGIWSMISERJ-UHFFFAOYSA-N 0.000 description 1
- URJOMNJCVJUXGX-UHFFFAOYSA-N N1(CCC1)C(CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)F)C(C)(F)F)=O Chemical compound N1(CCC1)C(CN1N=CC=2C1=NC(=CN=2)C1=CC(=C(C=C1)F)C(C)(F)F)=O URJOMNJCVJUXGX-UHFFFAOYSA-N 0.000 description 1
- 208000006633 Tonic-Clonic Epilepsy Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861681P | 2019-06-14 | 2019-06-14 | |
| US62/861,681 | 2019-06-14 | ||
| PCT/EP2020/066405 WO2020249802A1 (en) | 2019-06-14 | 2020-06-12 | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536773A JP2022536773A (ja) | 2022-08-18 |
| JPWO2020249802A5 true JPWO2020249802A5 (https=) | 2023-06-20 |
| JP2022536773A5 JP2022536773A5 (https=) | 2023-06-20 |
Family
ID=71111400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021574160A Withdrawn JP2022536773A (ja) | 2019-06-14 | 2020-06-12 | 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11993587B2 (https=) |
| EP (1) | EP3983413A1 (https=) |
| JP (1) | JP2022536773A (https=) |
| KR (1) | KR20220024403A (https=) |
| CN (1) | CN114008052A (https=) |
| AU (1) | AU2020292994A1 (https=) |
| BR (1) | BR112021024117A2 (https=) |
| CA (1) | CA3143105A1 (https=) |
| MX (1) | MX2021015500A (https=) |
| WO (1) | WO2020249802A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| CN113993868A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途 |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| KR20220024403A (ko) | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도 |
| CN113950357A (zh) | 2019-06-14 | 2022-01-18 | 詹森药业有限公司 | 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途 |
| SG11202112405VA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| EP4669318A1 (en) * | 2023-02-23 | 2025-12-31 | The Rockefeller University | 1-ACYL-3-AMINOINDAZOLES FOR THE TREATMENT OF CYSTIC FIBROSIS |
| KR20250094560A (ko) | 2023-12-15 | 2025-06-25 | 서울대학교산학협력단 | GluN2B 억제제를 유효성분으로 포함하는 페닐케톤뇨증 및 고페닐알라닌혈증의 뇌기능 장애 예방, 개선 또는 치료용 조성물 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT97888B (pt) | 1990-06-07 | 1998-12-31 | Zeneca Ltd | Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem |
| GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
| CA2262502C (en) | 1996-07-31 | 2002-11-26 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same |
| AU2001270149A1 (en) | 2000-06-26 | 2002-01-08 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| EP1490364B1 (en) | 2002-03-28 | 2007-09-26 | Eisai R&D Management Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| CA2482838A1 (en) | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Pyrazole compounds and pharmaceutical compositions containing the compound |
| WO2005028480A2 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| EP1720860A1 (en) | 2004-02-18 | 2006-11-15 | AstraZeneca AB | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| US7820654B2 (en) | 2004-09-23 | 2010-10-26 | Dr. Reddy's Laboratories Ltd. | Pyrimidine compounds, process for their preparation and compositions containing them |
| EP1814883A1 (en) | 2004-11-22 | 2007-08-08 | Vertex Pharmaceuticals Incorporated | Bicyclic inhibitors or rho kinase |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| TWI443090B (zh) | 2007-05-25 | 2014-07-01 | Abbvie Deutschland | 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物 |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| CN101842357A (zh) | 2007-08-30 | 2010-09-22 | 武田药品工业株式会社 | 取代的吡唑衍生物 |
| EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
| WO2009118187A1 (en) | 2008-03-27 | 2009-10-01 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| JPWO2009157196A1 (ja) | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| NZ590688A (en) | 2008-08-05 | 2012-09-28 | Daiichi Sankyo Co Ltd | imidazo[4,5-b]pyridin-2-one derivatives |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| RU2517181C2 (ru) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов |
| KR101048448B1 (ko) | 2008-11-21 | 2011-07-11 | 한국화학연구원 | 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CA2744498C (en) | 2008-11-25 | 2017-10-24 | University Of Rochester | Mlk inhibitors and methods of use |
| US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| EP2579717A4 (en) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
| WO2012102405A1 (ja) | 2011-01-28 | 2012-08-02 | 佐藤製薬株式会社 | 縮環化合物 |
| JP2012188363A (ja) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| CA2841981A1 (en) | 2011-07-28 | 2013-01-31 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| EP2570415B1 (en) | 2011-09-19 | 2015-08-26 | Sanofi | N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals |
| WO2013060029A1 (en) * | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Allosteric modulators of metabotropic glutamate receptors |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| SG11201505862TA (en) | 2013-01-29 | 2015-08-28 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| SG11201506687RA (en) | 2013-03-15 | 2015-09-29 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| CA2915838C (en) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| CA2918242C (en) | 2013-07-31 | 2022-06-21 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
| ES2791252T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Pirazoles |
| WO2016025917A1 (en) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| US12006328B2 (en) | 2014-11-18 | 2024-06-11 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto |
| MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
| HRP20200410T1 (hr) * | 2015-07-09 | 2020-08-21 | Janssen Pharmaceutica Nv | Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora |
| BR112018016329A2 (pt) | 2016-02-10 | 2018-12-18 | Janssen Pharmaceutica Nv | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| IL271149B2 (en) | 2017-06-14 | 2024-05-01 | Trevena Inc | Compounds for modulating s1p1 activity and methods of using the same |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| WO2019193516A2 (en) | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators |
| CN110294756A (zh) | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备 |
| SG11202112405VA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| CN113950357A (zh) | 2019-06-14 | 2022-01-18 | 詹森药业有限公司 | 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途 |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| CN113939306B (zh) | 2019-06-14 | 2024-07-19 | 德彪药业国际股份公司 | 用于治疗涉及生物膜的细菌感染的药物及其用途 |
| KR20220024403A (ko) | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도 |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| CN113993868A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途 |
| UY38806A (es) | 2019-08-01 | 2021-02-26 | Novartis Ag | Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos |
| EP4027993A4 (en) * | 2019-09-13 | 2023-09-20 | The Broad Institute Inc. | Cyclooxygenase-2 inhibitors and uses thereof |
| WO2021250521A1 (en) | 2020-06-09 | 2021-12-16 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
-
2020
- 2020-06-12 KR KR1020227000030A patent/KR20220024403A/ko not_active Withdrawn
- 2020-06-12 CA CA3143105A patent/CA3143105A1/en active Pending
- 2020-06-12 WO PCT/EP2020/066405 patent/WO2020249802A1/en not_active Ceased
- 2020-06-12 MX MX2021015500A patent/MX2021015500A/es unknown
- 2020-06-12 US US17/618,068 patent/US11993587B2/en active Active
- 2020-06-12 BR BR112021024117A patent/BR112021024117A2/pt not_active Application Discontinuation
- 2020-06-12 CN CN202080045034.6A patent/CN114008052A/zh active Pending
- 2020-06-12 AU AU2020292994A patent/AU2020292994A1/en not_active Abandoned
- 2020-06-12 EP EP20733915.1A patent/EP3983413A1/en not_active Withdrawn
- 2020-06-12 JP JP2021574160A patent/JP2022536773A/ja not_active Withdrawn
- 2020-06-12 US US16/899,847 patent/US11214563B2/en not_active Expired - Fee Related